INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $423 | -0.9% | 8,122 | +20.3% | 0.04% | -16.3% |
| Q2 2023 | $427 | +46.7% | 6,751 | +23.0% | 0.04% | +19.4% |
| Q4 2022 | $291 | -99.9% | 5,490 | -40.4% | 0.04% | -30.8% |
| Q1 2021 | $313,000 | +44.9% | 9,216 | -34.4% | 0.05% | -3.7% |
| Q1 2020 | $216,000 | -30.8% | 14,043 | -66.4% | 0.05% | +28.6% |
| Q3 2019 | $312,000 | +119.7% | 41,823 | +236.0% | 0.04% | +162.5% |
| Q4 2018 | $142,000 | -83.5% | 12,449 | -74.4% | 0.02% | -62.8% |
| Q2 2018 | $859,000 | -7.6% | 48,594 | +10.0% | 0.04% | -12.2% |
| Q1 2018 | $930,000 | -42.2% | 44,194 | -60.2% | 0.05% | -50.0% |
| Q4 2017 | $1,609,000 | +648.4% | 111,100 | +687.9% | 0.10% | +716.7% |
| Q3 2016 | $215,000 | -77.9% | 14,100 | -43.8% | 0.01% | -77.8% |
| Q2 2016 | $973,000 | +379.3% | 25,068 | +243.4% | 0.05% | +315.4% |
| Q1 2016 | $203,000 | – | 7,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |